This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TOBI Podhaler

Novartis AG

Drug Names(s): TMB100, TIP, Tobramycin (TOBI) dry powder formulation

Description: TIP is a dry powder formulation of tobramycin, used with a pocket-size, capsule-based inhaler. Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.

Deal Structure: In 2001, Chiron and Nektar initiated a collaboration to develop TIP.

In October 2008, Nektar transfered manufacturing and royalty rights to the Tobramycin inhalation powder (TIP) program to Novartis.

In December 2008, Nektar announced that it has closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash.


TOBI Podhaler News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug